# IL-10: Anti-Inflammatory Cytokine Homodimer, STAT3 Activation, and Immune Suppression


## Key Takeaways

- Interleukin-10 (IL-10) is a homodimeric cytokine encoded by the *IL10* gene at locus 1q32.1, functioning as a potent immunosuppressant by binding to a heterotetrameric receptor complex (IL-10Rα/β). This binding initiates signaling via the JAK/STAT pathway, primarily activating STAT3, which leads to the inhibition of pro-inflammatory cytokine synthesis (e.g., TNF-α, IL-1β) and suppression of antigen presentation.
- The *IL10* gene locus is subject to complex transcriptional regulation, including promoter polymorphisms (e.g., rs1800896, rs1800872) associated with differential IL-10 production and varying susceptibility to autoimmune diseases (SLE, RA), inflammatory bowel disease (IBD), and certain infections. Epigenetic modifications, such as promoter demethylation upon T-cell activation, are critical for acquiring IL-10 competence.
- Loss-of-function mutations in *IL10* or its receptor genes (*IL10RA*, *IL10RB*) are a rare but established cause of very early-onset inflammatory bowel disease (VEO-IBD), characterized by severe, refractory colitis presenting in infancy. This highlights the critical role of intact IL-10 signaling in maintaining intestinal immune homeostasis.
- IL-10's biological activity is mediated by its homodimeric structure, which presents two symmetric binding sites for IL-10Rα, initiating a cascade involving JAK1/Tyk2 phosphorylation of STAT3. Activated STAT3 translocates to the nucleus to modulate gene expression, suppressing NF-κB signaling and promoting mRNA degradation of pro-inflammatory mediators.
- Viral pathogens, such as Epstein-Barr virus (EBV) with its vIL-10 homolog (BCRF1), have evolved to mimic IL-10's immunosuppressive functions to evade host immunity, while bacterial and parasitic infections can induce host IL-10 production to dampen anti-pathogen responses.
- Therapeutic strategies involving recombinant IL-10 (rhIL-10) have shown mixed clinical efficacy due to side effects and short half-life, prompting exploration of gene therapy and cell-based approaches (e.g., IL-10-secreting MSCs or dendritic cells) for sustained, localized IL-10 delivery in inflammatory and autoimmune conditions.

---

## Executive Summary & Key Metadata

Interleukin-10 (IL-10) is a master regulatory cytokine encoded by the *IL10* gene, which is located on chromosome 1q32.1. The protein product is a homodimeric, non-covalent complex of two 178-amino-acid polypeptide chains, each adopting a canonical four-α-helix bundle topology. IL-10 exerts its biological activity by binding to a heterotetrameric receptor complex composed of two IL-10Rα (IL10RA) and two IL-10Rβ (IL10RB) subunits, which initiates a signaling cascade culminating in the activation of the JAK/STAT pathway, primarily STAT3. The downstream effects of IL-10 signaling are profoundly immunosuppressive and anti-inflammatory, including the inhibition of pro-inflammatory cytokine synthesis in macrophages and dendritic cells, the suppression of antigen presentation, and the regulation of B-cell and T-cell responses. Dysregulation of IL-10 expression or signaling is implicated in a broad spectrum of pathologies, including inflammatory bowel disease (IBD), autoimmune diseases, cancer, and susceptibility to infectious diseases.

| **Attribute** | **Value** |
| :--- | :--- |
| **HGNC Symbol** | IL10 |
| **UniProt Accession** | P22301 |
| **Representative PDB ID** | 1ILK |
| **Chromosomal Locus** | 1q32.1 |
| **Primary Molecular Function** | Cytokine activity; anti-inflammatory; inhibition of pro-inflammatory cytokine production |
| **Disease & Pathology Associations** | Very early-onset inflammatory bowel disease (VEO-IBD), Crohn's disease, ulcerative colitis, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, cancer, and susceptibility to various infections |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The *IL10* gene is located on the long (q) arm of chromosome 1 at cytogenetic band 1q32.1. The genomic coordinates (GRCh38/hg38) span approximately 5.2 kilobases (kb) from 206,767,602 to 206,772,792 on the forward strand. The gene is composed of five exons and four introns, a structure that is highly conserved among mammalian orthologs. The coding sequence is contained within a single open reading frame that begins in exon 1 and terminates in exon 5. The 5' untranslated region (UTR) is encoded by part of exon 1, while the 3' UTR is encoded by exon 5 and contains multiple AU-rich elements (AREs) that are critical for post-transcriptional regulation of mRNA stability and translation [1].

### 1.2 Promoter Architecture and Regulatory Elements

The promoter region of *IL10* is complex and contains numerous cis-acting regulatory elements that integrate signals from diverse transcription factors. The core promoter is located immediately upstream of the transcription start site (TSS) and lacks a canonical TATA box, instead relying on initiator (Inr) elements and downstream promoter elements (DPE) for basal transcription. The proximal promoter region, spanning approximately -1000 to +1 base pairs (bp) relative to the TSS, contains binding sites for a wide array of transcription factors, including Sp1, AP-1, C/EBP, NF-κB, and STAT family members.

Three well-characterized single nucleotide polymorphisms (SNPs) reside within the proximal promoter: rs1800896 (-1082A>G), rs1800871 (-819C>T), and rs1800872 (-592C>A). These SNPs are in strong [linkage disequilibrium](/knowledge/bioinformatics/linkage-disequilibrium-and-haplotype-mapping) and form common haplotypes (GCC, ACC, and ATA) that are associated with differential *IL10* transcriptional activity [2, 3]. The -1082A>G polymorphism is located within a putative binding site for the transcription factor Sp1, and the G allele has been associated with higher IL-10 production in vitro and in vivo [4, 5]. The -592C>A polymorphism is located within a negative regulatory region, and the A allele has been linked to lower IL-10 expression [6, 7].

Beyond the proximal promoter, several distal enhancer and silencer elements have been identified. A highly conserved region approximately -4 kb upstream of the TSS has been shown to contain binding sites for the transcription factors c-Maf and Blimp-1, which are critical for the high-level expression of IL-10 in T-helper 1 (Th1) cells [8]. Additionally, a polymorphic CA dinucleotide repeat (IL10.G) and a second polymorphic dinucleotide repeat (IL10.R) have been identified in the 5' flanking region, although their functional significance is less well defined [1, 9].

### 1.3 Epigenetic Regulation

The *IL10* locus is subject to dynamic epigenetic regulation, including DNA methylation and histone modification. In naïve T cells, the *IL10* promoter is hypermethylated and in a closed chromatin conformation, lacking DNase I hypersensitive (HS) sites [1]. Upon T-cell receptor (TCR) stimulation and differentiation into IL-10-producing effector or regulatory T cells, the promoter undergoes demethylation at specific CpG dinucleotides, particularly within the proximal promoter region, leading to chromatin remodeling and the establishment of DNase I HS sites [1, 2]. This demethylation is associated with increased gene expression and is a key step in the acquisition of IL-10 competence [3, 4].

The methylation status of the *IL10* gene in peripheral blood has been investigated as a potential biomarker for disease prognosis. In Graves' disease, for example, the methylation levels of *IL10* in peripheral blood were found to be related to the intractability of the disease, suggesting that epigenetic marks at this locus could serve as a prognostic indicator [3]. Similarly, in chronic lymphocytic leukemia (CLL), reduced DNA methylation of the *IL10* locus is associated with increased IL-10 production by the leukemic cells, particularly in the anergic IGHV-mutated subset [5].

### 1.4 Isoforms and Splice Variants

The *IL10* gene is not known to produce multiple protein-coding isoforms through alternative splicing. The primary transcript is processed to yield a single, well-defined mRNA species that encodes the 178-amino-acid IL-10 precursor protein. However, post-translational processing is critical for the production of the mature, secreted cytokine. The N-terminal 18 amino acids constitute a signal peptide that directs the nascent polypeptide into the endoplasmic reticulum (ER). This signal peptide is cleaved during translocation, yielding the mature 160-amino-acid protein that is secreted as a non-covalent homodimer.

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Post-Translational Modifications

The human IL-10 precursor is 178 amino acids in length. The mature, secreted protein is 160 amino acids long and has a molecular weight of approximately 18.5 kDa per monomer. The protein contains two conserved cysteine residues (Cys-62 and Cys-114 in the mature protein) that form a single intramolecular disulfide bond, which is essential for the correct folding and stability of the monomer. The protein is not glycosylated, which is unusual for a secreted cytokine.

### 2.2 Secondary and Tertiary Structure: The Four-Helix Bundle

The IL-10 monomer adopts a canonical cytokine fold: a compact bundle of four α-helices (designated A, B, C, and D) arranged in an up-up-down-down topology. The four helices are connected by loops of varying lengths. The A-B loop and the C-D loop are long and extend out from the core of the bundle, while the B-C loop is short. This fold is characteristic of the IL-10 family of cytokines, which also includes IL-19, IL-20, IL-22, IL-24, and IL-26.

### 2.3 Quaternary Structure: The Intercalating Homodimer

The biologically active form of IL-10 is a non-covalent homodimer. The dimerization interface is extensive and is formed by the intercalation of the A and D helices from one monomer with the corresponding helices from the second monomer. This "domain-swapped" arrangement creates a single, continuous hydrophobic core that stabilizes the dimer. The two monomers are arranged in an antiparallel fashion, resulting in a molecule with two-fold rotational symmetry. The dimer has a molecular weight of approximately 37 kDa and resembles two interlocking "V" shapes.

The quaternary structure is critical for receptor binding. The homodimer presents two symmetric binding sites for the IL-10Rα chain. Each binding site is formed by residues from both monomers, primarily from the A-B loop and the C-D loop of one monomer, and the A and D helices of the other. The high-affinity binding of IL-10 to IL-10Rα is a prerequisite for the subsequent recruitment of the IL-10Rβ chain and the initiation of signal transduction.

### 2.4 Receptor Binding Sites and Structural Basis of Signaling

The IL-10 homodimer binds to its receptor complex in a sequential manner. First, the dimer binds with high affinity (Kd ~ 50-200 pM) to two molecules of IL-10Rα (also known as IL-10R1). This binding is mediated primarily by the tips of the A-B and C-D loops of IL-10. The IL-10/IL-10Rα complex then recruits two molecules of IL-10Rβ (also known as IL-10R2), which binds with lower affinity. The formation of this hexameric complex (IL-10 dimer + 2x IL-10Rα + 2x IL-10Rβ) brings the intracellular domains of the receptor chains into close proximity, allowing for the trans-phosphorylation and activation of the receptor-associated Janus kinases (JAKs).

### 2.5 Interactive 3D Visualizer

To explore the three-dimensional structure of the IL-10 homodimer in detail, including its secondary structure elements, dimer interface, and receptor-binding surfaces, please use the interactive visualizer below.

[Interactive 3D Protein Visualizer: Load IL10 (PDB: 1ILK)](/tools/protein-structure-viewer?source=direct&pdbId=1ILK)

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The IL-10 Receptor Complex

IL-10 exerts its effects by binding to a specific cell-surface receptor complex. The receptor is a heterotetramer composed of two copies of the ligand-binding α chain (IL-10Rα, encoded by *IL10RA*) and two copies of the accessory β chain (IL-10Rβ, encoded by *IL10RB*). IL-10Rα is a 110-kDa transmembrane protein that is expressed on a wide variety of hematopoietic cells, including macrophages, dendritic cells, T cells, B cells, and natural killer (NK) cells. IL-10Rβ is a 100-kDa protein that is more ubiquitously expressed and is also a component of the receptor complexes for other IL-10 family cytokines, such as IL-22, IL-26, and IL-28.

### 3.2 JAK/STAT Signaling Cascade

The intracellular domains of IL-10Rα and IL-10Rβ are constitutively associated with the Janus kinases JAK1 and Tyk2, respectively. Upon IL-10 binding and receptor oligomerization, JAK1 and Tyk2 are brought into close proximity and trans-phosphorylate each other on specific tyrosine residues, leading to their activation. The activated JAKs then phosphorylate specific tyrosine residues on the intracellular tail of IL-10Rα, creating docking sites for the Src homology 2 (SH2) domain of the transcription factor STAT3.

STAT3 is recruited to the phosphorylated receptor and is subsequently phosphorylated by JAK1 on a critical tyrosine residue (Tyr-705). Phosphorylated STAT3 (pSTAT3) then dissociates from the receptor, forms homodimers, and translocates to the nucleus. In the nucleus, pSTAT3 dimers bind to specific DNA sequences known as gamma-activated sites (GAS) or STAT-binding elements (SBE) in the promoters of target genes, thereby modulating their transcription.

While STAT3 is the primary mediator of IL-10 signaling, other STAT family members, including STAT1 and STAT5, can also be activated to a lesser extent. The specific biological outcome of IL-10 signaling is largely determined by the balance of STAT3 versus STAT1 activation, with a high STAT3:STAT1 ratio favoring anti-inflammatory responses.

### 3.3 Transcriptional Targets and Anti-Inflammatory Mechanisms

The anti-inflammatory effects of IL-10 are primarily mediated by STAT3-dependent gene expression changes in innate immune cells, particularly macrophages and dendritic cells. IL-10 potently suppresses the production of a wide range of pro-inflammatory cytokines, including TNF-α, IL-1β, IL-6, IL-12, and IL-23. This suppression is achieved through multiple mechanisms:

1.  **Inhibition of NF-κB Signaling:** IL-10 signaling can inhibit the activation of NF-κB, a master transcription factor for pro-inflammatory genes. This is achieved in part by stabilizing the inhibitor of NF-κB (IκB-α), which sequesters NF-κB in the cytoplasm and prevents its nuclear translocation.
2.  **Suppression of Pro-Inflammatory Gene Transcription:** STAT3 can directly compete with other transcription factors for binding to overlapping promoter elements or can recruit co-repressor complexes that inhibit transcription.
3.  **Post-Transcriptional Regulation:** IL-10 can promote the degradation of pro-inflammatory cytokine mRNAs by destabilizing them. This is mediated by the induction of RNA-binding proteins, such as tristetraprolin (TTP), which bind to AREs in the 3' UTRs of target mRNAs and promote their deadenylation and decay.
4.  **Inhibition of Antigen Presentation:** IL-10 downregulates the expression of MHC class II molecules and co-stimulatory molecules (e.g., CD80, CD86) on the surface of antigen-presenting cells, thereby reducing their ability to activate T cells.

### 3.4 Effects on Adaptive Immune Cells

IL-10 has complex and context-dependent effects on T and B lymphocytes. It is a potent growth and differentiation factor for B cells, promoting their survival, proliferation, and differentiation into antibody-secreting plasma cells. It also promotes class-switch recombination to IgG1 and IgG3.

In contrast, IL-10 is a direct inhibitor of T-cell proliferation and cytokine production. It suppresses the production of IL-2 and IFN-γ by Th1 cells and inhibits the proliferation of CD4+ and CD8+ T cells. However, IL-10 also plays a critical role in the differentiation and function of regulatory T cells (Tregs), which are essential for maintaining immune tolerance and preventing autoimmunity. IL-10 can also enhance the cytotoxic activity of CD8+ T cells under certain conditions, particularly within the tumor microenvironment [6].

### 3.5 Regulation of IL-10 Expression

The expression of IL-10 is tightly regulated at multiple levels, including transcription, post-transcriptional processing, and protein secretion. A wide variety of stimuli can induce IL-10 production, including TLR ligands (e.g., LPS), cytokines (e.g., IL-12, IL-27), and engagement of co-stimulatory molecules. The transcription factors c-Maf, Blimp-1, and STAT3 are key positive regulators of *IL10* gene transcription [8]. Conversely, the expression of IL-10 is negatively regulated by the transcription factor Rev-erbα, which binds directly to a Rev-DR2 element in the proximal promoter and represses transcription [7]. Long non-coding RNAs (lncRNAs), such as AW112010, can also suppress IL-10 expression by recruiting histone demethylases to the locus [8].

### 3.6 Protein-Protein Interaction Networks

The IL-10 signaling pathway is a complex network of protein-protein interactions. Key nodes in this network include the ligand (IL-10), the receptor chains (IL-10Rα, IL-10Rβ), the JAKs (JAK1, Tyk2), the STATs (STAT3, STAT1, STAT5), and the negative regulators of the pathway, such as the suppressors of cytokine signaling (SOCS) proteins. SOCS3 is a particularly important negative regulator that is induced by IL-10 and inhibits JAK activity, providing a feedback loop that limits the duration and magnitude of the signal. The protein Y-box-binding protein 1 (YB-1) has also been shown to orchestrate the onset and resolution of renal inflammation via its regulation of the *IL10* gene [9].

```mermaid
sequenceDiagram
    participant APC as "Antigen-Presenting Cell"
    participant Tcell as "T Cell"
    participant Mφ as Macrophage
    participant IL10 as "IL-10"
    participant R as "IL-10 Receptor (IL-10Rα/β)"
    participant JAK as "JAK1/Tyk2"
    participant STAT3 as "STAT3"
    participant Nucleus as "Nucleus"
    Note over APC, Tcell: 1. Antigen presentation activates T cells
    APC->>Tcell: MHC-II + Co-stimulation
    Tcell->>Tcell: Differentiation (Th1, Th2, Treg)
    Tcell->>IL10: 2. Secretion of IL-10
    Mφ->>R: 3. IL-10 binds to receptor
    R->>JAK: 4. Receptor oligomerization & JAK activation
    JAK->>STAT3: 5. Phosphorylation of STAT3 (pSTAT3)
    STAT3->>Nucleus: 6. Dimerization & nuclear translocation
    Nucleus->>Nucleus: 7. Regulation of gene expression (↓ pro-inflammatory, ↑ anti-inflammatory)
    Nucleus-->>Mφ: 8. Suppression of TNF-α, IL-1β, IL-6, IL-12
```

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Loss-of-Function Mutations in *IL10* and Its Receptors

Homozygous or compound heterozygous loss-of-function mutations in the *IL10* gene itself are a rare but well-established cause of very early-onset inflammatory bowel disease (VEO-IBD), a severe and life-threatening condition that presents within the first months of life [1]. These mutations are typically nonsense, frameshift, or missense mutations that result in a complete absence of IL-10 protein or the production of a non-functional cytokine. The clinical phenotype is characterized by severe, refractory colitis, perianal fistulas, and folliculitis.

Mutations in the *IL10RA* and *IL10RB* genes, which encode the receptor chains, are a more common cause of VEO-IBD than mutations in the ligand itself [1, 2]. These mutations disrupt IL-10 signaling, leading to a similar clinical phenotype. The GENIUS Working Group has conducted extensive phenotypic characterization of patients with mutations in these three genes, confirming the critical role of the IL-10 signaling axis in intestinal immune homeostasis [1].

### 4.2 Common Promoter Polymorphisms and Disease Susceptibility

The common promoter SNPs (rs1800896, rs1800871, rs1800872) have been extensively studied for their association with a wide range of diseases, with often conflicting results. These polymorphisms are believed to influence IL-10 production levels, thereby modulating the intensity of inflammatory and immune responses.

- **Autoimmune Diseases:** The -1082A>G (rs1800896) polymorphism has been associated with susceptibility to and severity of several autoimmune diseases. The low-producing A allele has been linked to an increased risk of systemic lupus erythematosus (SLE) and higher disease activity [2, 3]. In rheumatoid arthritis (RA), the association has been inconsistent, but some studies have found an association with the low-producing genotype in specific populations [3, 4]. In multiple sclerosis (MS), reduced *IL10* gene expression in pro-inflammatory Th17 cells has been observed, and promoter polymorphisms have been linked to cognitive function in patients [5, 6].
- **Inflammatory Bowel Disease (IBD):** The rs3024505 (C>T) polymorphism, located downstream of the *IL10* gene, has been robustly associated with Crohn's disease (CD) and ulcerative colitis (UC) in multiple genome-wide association studies (GWAS) [7, 8]. This SNP disrupts a STAT3 binding site in B cells, leading to IL-10 dysregulation [8].
- **Infectious Diseases:** IL-10 promoter polymorphisms have been associated with susceptibility to and severity of various infectious diseases. The -592C>A polymorphism has been associated with susceptibility to chronic hepatitis C and B [1, 2, 3, 9]. In tuberculosis, certain IL-10 haplotypes have been associated with protection or susceptibility, depending on the population studied [4, 5]. The -1082A>G polymorphism has also been linked to the severity of respiratory syncytial virus (RSV) bronchiolitis and the etiology of infant bronchiolitis [6, 7].
- **Cancer:** IL-10 promoter polymorphisms have been investigated as risk factors for various cancers, including cervical cancer, gastric cancer, colorectal cancer, and non-small cell lung cancer [4, 6, 7, 8, 9]. The results have been inconsistent, but a meta-analysis of the -1082A>G polymorphism suggests that the low-producing A allele may be associated with an increased risk of certain cancers. The -1082G allele has been associated with cancer cachexia in gastroesophageal malignancy [5].
- **Other Conditions:** IL-10 polymorphisms have also been associated with asthma phenotypes in children, atopic diseases, metabolic syndrome, pre-eclampsia, and acute coronary syndrome [1, 2, 3, 4, 5]. The -1082A>G polymorphism has been linked to the risk of postmenopausal osteoporosis [6].

### 4.3 Functional Impact of the rs3024505 (C/T) Polymorphism

The rs3024505 (C/T) polymorphism is located approximately 4 kb downstream of the *IL10* gene. Recent functional studies have demonstrated that this SNP disrupts a STAT3 binding site in B cells, leading to reduced IL-10 expression and dysregulation of the immune response [8]. This finding provides a mechanistic link between this non-coding polymorphism and its strong genetic association with inflammatory diseases such as SLE and IBD.

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral IL-10 Homologs

Several viruses have evolved strategies to manipulate the host immune system by encoding viral homologs of IL-10 (vIL-10). The most well-characterized vIL-10 is encoded by the Epstein-Barr virus (EBV) *BCRF1* gene. The EBV vIL-10 shares approximately 84% amino acid sequence identity with human IL-10 and can bind to the human IL-10 receptor, albeit with lower affinity. It retains some of the immunosuppressive functions of human IL-10, such as inhibiting pro-inflammatory cytokine production, but lacks the ability to stimulate B-cell proliferation and antibody production. This allows the virus to suppress cell-mediated immunity while avoiding the enhancement of humoral immunity that could be detrimental to viral persistence.

Other viruses, including cytomegalovirus (CMV), equine herpesvirus type 2 (EHV-2), and [African swine fever virus](/knowledge/viruses/livestock-viruses/african-swine-fever-virus) (ASFV), also encode IL-10-like proteins [7, 8]. The EHV-2 genome harbors an IL-10-like gene, and ASFV infection has been shown to induce IL-10 expression in infected macrophages, which may contribute to immune evasion [7, 8].

### 5.2 Bacterial and Parasitic Modulation of IL-10

Many bacterial and parasitic pathogens exploit the IL-10 pathway to evade host immune responses. *Mycobacterium tuberculosis*, the causative agent of tuberculosis, can induce IL-10 production by host macrophages, which suppresses the anti-mycobacterial immune response and promotes bacterial survival [7]. The repression of the human *IL10* gene by Rev-erbα has been shown to ameliorate *M. tuberculosis* clearance, highlighting the importance of this pathway in host defense [7]. *Mycobacterium leprae*, the cause of leprosy, is also associated with IL-10 production, and IL-10 haplotypes have been investigated as potential protective factors [4, 9].

In the gut, the absence of IL-10 in gene-deficient mice leads to spontaneous colitis, driven by an aberrant immune response to the commensal microbiota [1, 2, 3]. The gut microbiota composition is altered in these mice, and this precedes the onset of colitis, suggesting a complex interplay between IL-10, the microbiome, and the host immune system [1].

### 5.3 IL-10 in Viral Pathogenesis

IL-10 plays a complex role in viral infections. On one hand, it can limit immunopathology by suppressing excessive inflammation. On the other hand, it can promote viral persistence by suppressing antiviral immune responses. In HIV infection, IL-10 promoter polymorphisms have been associated with the rate of disease progression [4]. In hepatitis B and C virus infections, IL-10 polymorphisms influence the outcome of infection, including the risk of chronicity and the severity of liver fibrosis [1, 2, 3, 5, 6]. In COVID-19, IL-10 gene polymorphisms have been linked to the severity of infection and mortality [7].

## 6. [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), Drug Targets & Small-Molecule Inhibitors

### 6.1 Recombinant IL-10 and IL-10-Based Therapies

Given its potent anti-inflammatory properties, recombinant human IL-10 (rhIL-10) has been investigated as a therapeutic agent for various inflammatory and autoimmune diseases. However, clinical trials have yielded mixed results. While rhIL-10 showed some efficacy in treating psoriasis and Crohn's disease, its use was limited by significant side effects, including anemia, thrombocytopenia, and flu-like symptoms. The systemic administration of IL-10 is also complicated by its short half-life and pleiotropic effects.

### 6.2 IL-10 Gene Therapy

Gene therapy approaches aimed at delivering the *IL10* gene to specific tissues or cells are being explored as a way to achieve sustained, local IL-10 production. Adeno-associated virus (AAV) vectors encoding IL-10 have been shown to be effective in preclinical models of autoimmune diseases, such as [equine recurrent uveitis](/knowledge/veterinary-medicine/equine-care/equine-recurrent-uveitis-diagnosis-long-term-monitoring-eye-preservation) (ERU) and experimental autoimmune uveitis [8]. Intravitreal injection of AAV-Equine-IL10 was effective in inhibiting experimental autoimmune uveitis [8]. AAV vectors have also been used to prepare IL-10-secreting human neural stem cell-based therapeutics [9]. In a nonhuman primate model of AAV-based gene transfer, IL-10-treated dendritic cells were generated and evaluated for their ability to modulate immune responses [1].

### 6.3 Cell-Based Therapies

Cell-based therapies using IL-10-secreting cells are also under investigation. Mesenchymal stem cells (MSCs) engineered to overexpress IL-10 have shown therapeutic efficacy in a rat model of collagen-induced arthritis [2]. Tolerogenic dendritic cells (tolDCs) that constitutively secrete IL-10 have been generated and shown to inhibit memory T-cell activation [3].

### 6.4 Targeting IL-10 in Cancer

The role of IL-10 in cancer is complex and context-dependent. While IL-10 can suppress anti-tumor immune responses, it can also enhance the activity of CD8+ T cells within the tumor microenvironment [6]. This has led to the development of IL-10-based therapies for cancer. PEGylated IL-10 (PEG-IL-10, pegilodecakin) has been investigated in clinical trials for the treatment of various solid tumors. The results have shown modest anti-tumor activity, and further research is needed to identify biomarkers that can predict which patients are most likely to benefit.

Conversely, strategies to inhibit IL-10 signaling are being explored as a way to enhance anti-tumor immunity. Monoclonal antibodies against IL-10 or its receptor could potentially block the immunosuppressive effects of IL-10 in the tumor microenvironment, thereby enhancing the efficacy of other immunotherapies, such as immune checkpoint inhibitors. However, these approaches are still in the early stages of development.

### 6.5 Pharmacogenomic Considerations

The [pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles) of IL-10 is an emerging field. The promoter polymorphisms that affect IL-10 production may influence the response to IL-10-targeted therapies. For example, patients with a high-producing genotype may be less likely to benefit from IL-10 supplementation, while those with a low-producing genotype may be more likely to respond. Similarly, the response to IL-10 inhibitors in cancer may be influenced by the patient's IL-10 genotype. The association of IL10 and IL10 receptor gene variation with outcomes after hematopoietic cell transplantation has also been investigated, suggesting a role for IL-10 genotyping in transplant medicine [4].

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Identifier** | **URL** |
| :--- | :--- | :--- |
| **NCBI Gene** | 3586 | [https://www.ncbi.nlm.nih.gov/gene/3586](https://www.ncbi.nlm.nih.gov/gene/3586) |
| **Ensembl** | ENSG00000136634 | [https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000136634](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000136634) |
| **UniProt** | P22301 | [https://www.uniprot.org/uniprotkb/P22301/entry](https://www.uniprot.org/uniprotkb/P22301/entry) |
| **RCSB PDB** | 1ILK | [https://www.rcsb.org/structure/1ILK](https://www.rcsb.org/structure/1ILK) |
| **OMIM** | 124092 | [https://www.omim.org/entry/124092](https://www.omim.org/entry/124092) |
| **HGNC** | 5962 | [https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5962](https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5962) |
| **ClinVar** | (Search for IL10) | [https://www.ncbi.nlm.nih.gov/clinvar/?term=IL10%5Bgene%5D](https://www.ncbi.nlm.nih.gov/clinvar/?term=IL10%5Bgene%5D) |
| **STRING** | 9606.ENSP00000237522 | [https://string-db.org/network/9606.ENSP00000237522](https://string-db.org/network/9606.ENSP00000237522) |
| **BioGRID** | 10816 | [https://thebiogrid.org/10816](https://thebiogrid.org/10816) |

### Gene Ontology (GO) Terms

| **Ontology** | **Term** | **Accession** |
| :--- | :--- | :--- |
| **Molecular Function** | Cytokine activity | GO:0005125 |
| **Molecular Function** | Interleukin-10 receptor binding | GO:0005143 |
| **Biological Process** | Immune response | GO:0006955 |
| **Biological Process** | Inflammatory response | GO:0006954 |
| **Biological Process** | Negative regulation of inflammatory response | GO:0050728 |
| **Biological Process** | Regulation of cell population proliferation | GO:0042127 |
| **Biological Process** | Positive regulation of B cell proliferation | GO:0030890 |
| **Cellular Component** | Extracellular space | GO:0005615 |
| **Cellular Component** | Extracellular region | GO:0005576 |

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)

## References

[1] Kinoshita, R., Inoue, N., Iwatani, Y., Noguchi, Y., Hidaka, Y., & Watanabe, M. (2024). Methylation levels of the IL10 gene in peripheral blood are related to the intractability of Graves' disease. *Clinical Immunology*. [URL](https://www.semanticscholar.org/paper/ac2fa56de8efeca0e9609817b89d82f474cc9bd1)

[2] Hoshino, A., Takahashi, N., Oka, A., & Mizuguchi, M. (2023). Association of IL6 and IL10 gene promotor polymorphisms with susceptibility to acute necrotizing encephalopathy. *Frontiers in Neuroscience*. [URL](https://www.semanticscholar.org/paper/9a2e039628c18bccda24e6bcca6274985c7743cd)

[3] Crabtree, E., Uribe, K., Smith, S. M., Roberts, D., Salmon, J., Bower, J., Song, L., Bastola, P., Hirsch, M., & Gilger, B. (2022). Inhibition of experimental autoimmune uveitis by intravitreal AAV-Equine-IL10 gene therapy. *PLoS ONE*. [URL](https://www.semanticscholar.org/paper/c0f5275427dfab071b0d3c5f700624b44a1b5ea9)

[4] Datta, A., Zahora, F. T., Aziz, M. A., Uddin, M. S., Ferdous, M., Millat, M. S., Sarwar, M. S., Barek, M. A., Jafrin, S., Nahar, S., & Islam, M. S. (2020). Association study of IL10 gene polymorphisms (rs1800872 and rs1800896) with cervical cancer in the Bangladeshi women. *International Immunopharmacology*. [URL](https://www.semanticscholar.org/paper/e22ae5c46299e4759c45da6352c0fdfdb69f61ec)

[5] Hu, D., Notarbartolo, S., Croonenborghs, T., Patel, B., Cialic, R., Yang, T.-H., Aschenbrenner, D., Andersson, K., Gattorno, M., Pham, M. C., Kivisakk, P., Pierre, I. V., Lee, Y., Kiani, K., Bokarewa, M., Tjon, E. C., Pochet, N., Sallusto, F., Kuchroo, V., & Weiner, H. (2017). Transcriptional signature of human pro-inflammatory TH17 cells identifies reduced IL10 gene expression in multiple sclerosis. *Nature Communications*. [URL](https://www.semanticscholar.org/paper/faf304f1ff93ae92783d0cb27fa8845cbec2653c)

[6] Wang, J., Djudjaj, S., Gibbert, L., Lennartz, V., Breitkopf, D., Rauen, T., Hermert, D., Martin, I. V., Boor, P., Braun, G., Floege, J., Ostendorf, T., & Raffetseder, U. (2017). YB‐1 orchestrates onset and resolution of renal inflammation via IL10 gene regulation. *Journal of Cellular and Molecular Medicine*. [URL](https://www.semanticscholar.org/paper/53271b5c3199b3fa7ad2003adea4088a57d18a18)

[7] Miyoshi, J., Lee, S. T. M., Kennedy, M. S., Puertolas, M. V., Frith, M., Koval, J., Miyoshi, S., Antonopoulos, D., Leone, V., & Chang, E. (2020). Metagenomic Alterations in Gut Microbiota Precede and Predict Onset of Colitis in the IL10 Gene-Deficient Murine Model. *bioRxiv*. [URL](https://www.semanticscholar.org/paper/f2be0c5443739a5ebcfc9cc07c32a333e8350598)

[8] Liu, S., Liu, J.-w., Sun, L.-p., Gong, Y.-h., Xu, Q., Jing, J.-j., & Yuan, Y. (2018). Association of IL10 gene promoter polymorphisms with risks of gastric cancer and atrophic gastritis. *Journal of International Medical Research*. [URL](https://www.semanticscholar.org/paper/e59a1bcb4247366f9779c1c0383f30c7404892b5)

[9] Norde, M. M., Oki, É., Carioca, A. A. F., Damasceno, N. R. T., Fisberg, R., Marchioni, D